Revised CAR-T therapy eliminates dangerous cytokine release syndrome in lymphoma trial

Autologous CAR-T treatments for leukemia and lymphoma have offered new hope for patients, but the cell therapies can cause a dangerous immune reaction called cytokine release syndrome (CRS). Researchers at the University of Southern California (USC) Norris Comprehensive Cancer Center have designed a new type of CAR-T therapy to eliminate that side effect. CRS is a systemic inflammatory response...